First-in-Class Drug for ADHD Wins FDA Approval

(MedPage Today) -- The FDA approved oral centanafadine (Simtriyo), a first-in-class triple reuptake inhibitor for attention deficit-hyperactivity disorder (ADHD), Otsuka announced late last week.
The once-daily extended-release capsule--a...